Healthcare / BiotechnologyTokyo
$2513.00
+166.00 (+7.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.9B · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-51.5%
↓Gross Margin
100.0%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-69.2%
FCF CAGR
—
FCF margin
-6809.6%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28.5M · net income $-2.06B · FCF $-1.94B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $28.5M | $28.5M | $31.4M | $63.0M | $976.2M |
| Net Income | $-2.06B | $-2.06B | $-1.68B | $-1.94B | $-1.15B |
| EBITDA | $-2.05B | $-2.05B | $-1.68B | $-1.93B | $-1.14B |
| EPS | -80.00 | -80.00 | -77.17 | -108.92 | -66.31 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 48.5% | 34.7% |
| Operating Margin | -7090.5% | -7090.5% | -5357.5% | -3061.6% | -123.4% |
| Net Margin | -7209.6% | -7209.6% | -5368.3% | -3075.1% | -117.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.12 | 0.21 | 0.18 |
| Current Ratio | 6.62 | 6.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.94B | $-1.94B | $-2.02B | $-1.34B | $-1.72B |
| Returns | |||||
| ROE | -51.5% | -51.5% | -61.2% | -131.5% | -53.2% |
| Valuation | |||||
| P/B | 16.16 | 16.16 | 4.11 | 7.00 | 4.25 |
| Growth & Yield | |||||
| Revenue Growth | -9.0% | -9.0% | -50.2% | -93.5% | — |
| EPS Growth | -3.7% | -3.7% | 29.1% | -64.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+380.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-77.17 → -80.00
Residual
+380.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.